Skip to main content

The world’s first needle-free continuous glucose monitor to prevent and manage diabetes at scale

Objective

Diabetes is one of the biggest health concerns globally: 6% of the world’s population already lives with diabetes, and another 35% is at a high risk of developing it.
Proper management of diabetes starts with consistent and accurate monitoring of glucose levels. Yet, most diagnosed diabetics do not monitor their blood sugar as often as prescribed, because it is painful and inconvenient to do so. This is clear evidence that the €16+ billion glucose monitors industry needs a change – the current methods are not good enough.
We have invented, patented and productized a new technology category for extracting and analysing blood sugar levels in a completely non-invasive way. We are applying for the EIC blended finance to further miniaturise, optimise, and clinically prove this technology on a wider scale. The financing will turn our break-through scientific discovery into an end user device that can potentially impact over 2 billion people by helping them prevent diabetes onset altogether.

Coordinator

GLUCOMODICUM OY
Net EU contribution
€ 2 500 000,00
Address
A.i. Virtasenaukio 1
00560 Helsinki
Finland

See on map

Region
Manner-Suomi Helsinki-Uusimaa Helsinki-Uusimaa
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 4 067 443,75